Michael Hallek

Active 1992–2026

321
Papers
59,750
Citations
125
h-index
313
i10-index

Citations

Citations per year for Michael Hallek1976: 1 citations1979: 1 citations1992: 1 citations1993: 5 citations1994: 19 citations1995: 28 citations1996: 33 citations1997: 35 citations1998: 31 citations1999: 41 citations2000: 65 citations2001: 69 citations2002: 113 citations2003: 154 citations2004: 115 citations2005: 182 citations2006: 147 citations2007: 128 citations2008: 250 citations2009: 209 citations2010: 230 citations2011: 267 citations2012: 334 citations2013: 345 citations2014: 417 citations2015: 586 citations2016: 510 citations2017: 552 citations2018: 613 citations2019: 1,736 citations2020: 2,146 citations2021: 2,162 citations2022: 1,662 citations2023: 1,078 citations2024: 1,922 citations2025: 883 citations2026: 42 citations1977–1978: no citations, so these years are not shown1980–1991: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,745 citing papers, 24.4% of this breakdownGermany: 1,741 citing papers, 9% of this breakdownChina: 1,380 citing papers, 7.1% of this breakdownUnited Kingdom: 1,298 citing papers, 6.7% of this breakdownItaly: 1,204 citing papers, 6.2% of this breakdownFrance: 943 citing papers, 4.8% of this breakdownSpain: 678 citing papers, 3.5% of this breakdownAustralia: 580 citing papers, 3% of this breakdownNetherlands: 577 citing papers, 3% of this breakdownSwitzerland: 518 citing papers, 2.7% of this breakdownCanada: 516 citing papers, 2.6% of this breakdownJapan: 424 citing papers, 2.2% of this breakdown
0%24.4%Other 24.8%

Fields

  • Medicine62.8%
  • Biochemistry, Genetics and Molecular Biology26.8%
  • Immunology and Microbiology6.7%
  • Computer Science0.7%
  • Neuroscience0.6%
  • Engineering0.4%
  • Other2%

Topics

  • Chronic Lymphocytic Leukemia Research8.4%
  • Lymphoma Diagnosis and Treatment6.1%
  • Lung Cancer Research Studies2.8%
  • CAR-T cell therapy research2.5%
  • Virus-based gene therapy research2.3%
  • Immune Cell Function and Interaction2.2%
  • Other75.7%

Coauthors

All papers

Open in search
  1. Comprehensive genomic profiles of small cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Danila Seidel, Berit Pinther, Philipp Schaub, Christian Becker, Janine Altmüller, Jun Yokota, Takashi Kohno, Reika Iwakawa, Koji Tsuta, Masayuki Noguchi, Thomas Muley, Hans Hoffmann, Philipp A. Schnabel, Iver Petersen, Yuan Chen, Alex Soltermann, Verena Tischler, Chang‐Min Choi, Yong‐Hee Kim, Pierre P. Massion, Yong Zou, Dragana J. Jovanović, Milica Kontić, Gavin Wright, Prudence A. Russell, Benjamin Solomon, Ina Koch, Michael Lindner, Lucia Anna Muscarella, Annamaria la Torre, John K. Field, Marko Jakopović, Jelena Knežević, Esmeralda Castaños‐Vélez, Luca Roz, Ugo Pastorino, O.T. Brustugun, Marius Lund‐Iversen, Erik Thunnissen, Jens Köhler, Martin Schüler, Johan Botling, Martin Sandelin, Montse Sánchez‐Céspedes, Helga B. Salvesen, Viktor Achter, Ulrich Lang, Magdalena Bogus, Peter M. Schneider, Thomas Zander, Sascha Ansén, Michael Hallek, Jürgen Wolf, Martin Vingron, Yasushi Yatabe, William D. Travis, Peter Nürnberg, Christian Reinhardt, Sven Perner, Lukas C. Heukamp, Reinhard Büttner, Stefan A. Haas, Élisabeth Brambilla, Martin Peifer, Julien Sage, Roman K. Thomas - Nature 2015 cited by 2,428

  2. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Authors: , , , , , , , , , , , , , , , , , - Blood 2018 cited by 1,689

  3. Extracellular vesicle measurements with nanoparticle tracking analysis – An accuracy and repeatability comparison between NanoSight NS300 and ZetaView

    Authors: , , , , , , , , , , - Journal of Extracellular Vesicles 2019 cited by 626

  4. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Harry R. Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna‐Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens‐Martin Wendtner, Karl Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark‐David Levin, Marinus van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek - New England Journal of Medicine 2023 cited by 291

  5. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mehrdad Mobasher, Michael Hallek - New England Journal of Medicine 2019 cited by 852

  6. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shantanu Banerji, Gad Getz, Kwon-Sik Park, Daniel Rauh, Christian Grütter, Matthias Fischer, Laura Pasqualucci, Gavin Wright, Zoe Wainer, Prudence A. Russell, Iver Petersen, Yuan Chen, Erich Stoelben, Corinna Ludwig, Philipp A. Schnabel, Hans Hoffmann, Thomas Muley, Michael Brockmann, Walburga Engel-Riedel, Lucia Anna Muscarella, Vito Michele Fazio, Harry J.M. Groen, Wim Timens, Hannie Sietsma, Erik Thunnissen, Egbert F. Smit, Daniëlle A.M. Heideman, Peter J.F. Snijders, Federico Cappuzzo, Claudia Ligorio, Stefania Damiani, John K. Field, Steinar Solberg, Odd Terje Brustugun, Marius Lund‐Iversen, Jörg Sänger, Joachim H. Clement, Alex Soltermann, Holger Moch, Walter Weder, Benjamin Solomon, Jean‐Charles Soria, Pierre Validire, Benjamin Besse, Élisabeth Brambilla, Christian Brambilla, Sylvie Lantuéjoul, Philippe Lorimier, Peter M. Schneider, Michael Hallek, William Pao, Matthew Meyerson, Julien Sage, Jay Shendure, Robert C. Schneider, Reinhard Büttner, Jürgen Wolf, Peter Nürnberg, Sven Perner, Lukas C. Heukamp, Paul K. Brindle, Stefan A. Haas, Roman K. Thomas - Nature Genetics 2012 cited by 1,418

  7. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Regional Health - Europe 2021 cited by 747

  8. Mutations driving CLL and their evolution in progression and relapse

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Catherine J. Wu - Nature 2015 cited by 1,078

  9. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , - Annals of Oncology 2020 cited by 568

  10. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures

    Authors: , - American Journal of Hematology 2021 cited by 381

  11. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 cited by 1,684

  12. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 cited by 1,500

  13. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 cited by 796

  14. Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Cell 2019 cited by 239

  15. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

    Authors: , , , , , , , , , , - Blood 2008 cited by 3,193

  16. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 cited by 327

  17. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Barbara Eichhorst, Roland T. Ullrich, Marco Herling, Hans Christian Reinhardt, Michael Hallek, Michal R. Schweiger, Lukas P. Frenzel - Blood 2022 cited by 131

  18. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2023 cited by 93

  19. Molecular map of chronic lymphocytic leukemia and its impact on outcome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael Hallek, Chip Stewart, Donna Neuberg, José I. Martín‐Subero, Xosé S. Puente, Stephan Stilgenbauer, Catherine J. Wu, Elı́as Campo, Gad Getz - Nature Genetics 2022 cited by 148

  20. Chronic lymphocytic leukaemia

    Authors: , , - The Lancet 2018 cited by 370

  21. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 313

  22. Toll–Like Receptor 2–Mediated Innate Immune Response in Human Nonparenchymal Liver Cells Toward Adeno–Associated Viral Vectors

    Authors: , , , , , , , , , , , , , - Hepatology 2011 cited by 210

  23. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 142

  24. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Blood 2015 cited by 700